Source: ERS Lung Science Conference 2021
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Giulia Raggi, Switzerland. PP129 – Safety evaluation of cancer immunotherapy in a lung-on-chip model: the therapeutic FOLR1 targeting T Cell Bispecific antibody. ERS Lung Science Conference 2021

Member's Comments

No comment yet.

Related content which might interest you: A patient-derived lung-on-chip model to evaluate on-target/off-tumour toxicity of the therapeutic FOLR1-targeting T-Cell Bispecific antibody Source: Virtual Congress 2021 – In vitro modelling of lung disease: reach out to the next dimension Year: 2021 Reversing the suppression of T-cells: the role of monoclonal antibodies Source: International Congress 2015 – Stop immune tolerance in lung cancer! Year: 2015 Late Breaking Abstract - Preclinical study of anti-interleukin-4 alpha single domain antibody with therapeutic potential in asthma by oral inhalation Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 B-cell suppressive therapy and monoclonal antibodies in CTD: does one size fit all? Source: Virtual Congress 2020 – Rheumatology: understanding connective tissue disease in patients with interstitial lung disease Year: 2020 Interleukin 27 (IL27) as a novel therapeutic tool in lung cancer immune therapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Immunoglobulin-like transcripts 3 (ILT3) expression in human lung adenocarcinoma as a novel regulator of intratumoral lymphoid follicle formation Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Determination of antibodies against the red meat derived antigen Neu5Gc in patients with lung cancer. Probable association with disease development and progress Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Efficacy and safety of anti-PD-L1 antibody in NSCLC patients who previously treated with anti PD-1 antibodies Source: International Congress 2019 – Treatment of lung cancer Year: 2019 New concepts in pulmonary oncology Source: ISSN=ISSN 1025-448x, ISBN=ISBN 978-1-904097-51-8, page=63 Year: 2007 Phenotype pattern of human non-small cell lung cancer (NSCLC) model line in immune escape phenomenon. Effect of transfection with plasmids encoding specific anti-EGFR1 and anti-HER2/neu short hairpin (SH)RNA sequences Source: Annual Congress 2009 - Basic science and lung cancer Year: 2009 A novel anti-IgE immunotherapeutic, RP01, induces anti-IgE antibodies in human subjects; data from a phase I study Source: Eur Respir J 2007; 30: Suppl. 51, 622s Year: 2007 XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Microbial analysis in lung cancer according to PD-L1 level and immunotherapy response Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021 Correlation of IL-17A concentration with T regulatory cells in lung cancer microenvironment Source: International Congress 2016 – Lung cancer and immune cells: friends or foes? Year: 2016 Association of antiPD1 immunotherapy with immunogenic cell death-inducing chemotherapy in a murine model of squamous cell lung cancer Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018 The role of CD40 molecule in human lung cancer and its application in immunotherapy Source: Eur Respir J 2003; 22: Suppl. 45, 199s Year: 2003 Antitumor efficacy of the double suicide genesin lung cancer cells Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Antitumor effect of a humanized antibody against aminopeptidase N in mouse tumor models. Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014